Susmed

Susmed EBIT Margin

The EBIT Margin (Operating Margin) of Susmed (4263.T) as of Oct 29, 2026 is -66.40 %. In the previous year, EBIT Margin (Operating Margin) was -64.68 % — a change of 2.66% (lower).

EBIT Margin

-66.40 %

YoY

2.66%

Last updated:

EBIT Margin (Operating Margin) of Susmed is 2026 -66.40 % . EBIT Margin (Operating Margin) of Susmed was 2025 -64.68 % . It decreases by 2.66% lower compared to the previous year.

For Susmed, the operating (EBIT) margin of -66.4% is up versus -73.6% a few years ago.

The Susmed EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2020
-460.70 JPY
Jan 1, 2021
-288.70 JPY
Jan 1, 2022
-73.58 JPY
Jan 1, 2023
-9.34 JPY
Jan 1, 2024
-106.54 JPY
Jan 1, 2025
-64.68 JPY
Jan 1, 2026
-66.40 JPY
The Susmed EBIT Margin history
YEAREBIT MarginYoY
-66.40 %+2.66%
-64.68 %-39.29%
-106.54 %+1,041.23%
-9.34 %-87.31%
-73.58 %-74.51%
-288.70 %-37.33%
-460.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Susmed Stock analysis

What does Susmed do? SUSMED, Inc. generates revenue through its DTx Product segment, which develops application software for treating insomnia, breast cancer, and chronic kidney diseases. The DTx Platform segment provides clinical trial systems, machine learning analysis systems, and DTx development support services. The company's primary customers are healthcare providers and pharmaceutical companies seeking digital therapeutics solutions. SUSMED targets the healthcare technology market with its specialized software and support services for disease treatment and clinical research. The DTx Product segment focuses on creating therapeutic applications for specific medical conditions, while the DTx Platform segment offers infrastructure for clinical trials and machine learning analysis. SUSMED's business model relies on selling both its proprietary software products and platform services to healthcare institutions and pharmaceutical firms. The company's revenue streams include software licensing, system subscriptions, and development support fees. SUSMED's products are designed to address chronic conditions like insomnia and breast cancer, with additional focus on chronic kidney diseases. The DTx Platform serves as a comprehensive solution for clinical trial management and machine learning-driven analysis, supporting pharmaceutical companies in their drug development processes. The company's services are tailored to meet the needs of healthcare technology providers and pharmaceutical developers. Susmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Susmed stock

EBIT Margin (Operating Margin) of Susmed is -66.40 % in 2026.

EBIT Margin (Operating Margin) of Susmed changed from -64.68 % to -66.40 %, representing a 2.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Susmed since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Susmed with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Susmed

All Key Metrics — Susmed